Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish

Drugmaker Novo Nordisk (NVO), on Thursday, announced a $199-per-month offer for self-paying patients new to its weight loss drug Wegovy.

The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. It is valid for the first month only, after which self-paying customers have to pay $499 a month.

Thursday marks the FDA-imposed deadline for outsourcing facilities to stop compounding Semaglutide, the active ingredient in Wegovy.

“We are doubling down on our commitment to accessibility, availability, and affordability of authentic, FDA-approved Wegovy,” said Dave Moore, executive vice president of US operations for Novo Nordisk.

Patients can activate the one-time offer through the Wegovy website, the company’s NovoCare Pharmacy, or telehealth providers integrated with NovoCare Pharmacy.

Compounded Semaglutide became popular when Wegovy was in short supply. The FDA declared that the shortage had been resolved in February earlier this year and gave outsourcing facilities making compounded Semaglutide in bulk until May 22 to stop.

Novo Nordisk said on Thursday that the company continues to invest in correcting misinformation and educating communities on the risks of knock-off Semaglutide. The company also intends to launch an advertising campaign later this month, emphasizing the importance of using FDA-approved treatments like Wegovy.

On Stocktwits, retail sentiment around Novo Nordisk shares stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.

NVO stock is down by about 23% this year and 50% over the past 12 months.

Also See: Lawrence Summers Says US Looks Like A Developing Nation Where Stocks, Bonds, Currency Move Together: ‘That Has To Be Scary’

For updates and corrections, email newsroom[at]stocktwits[dot]com.